Therapeutic effect of liraglutide on expression of CTGF and BMP‐7 in induced diabetic nephropathy

Introduction Diabetic nephropathy (DN) is one of the critical complications of diabetes mellitus and the main cause of chronic renal dysfunction. The pathogenic mechanism causing the disease remains unclear and there is a lack of effective treatment methods so novel strategies are needed for DN management. The aim of this study, therefore, is to evaluate the effect of liraglutide as glucagon‐like peptide‐1 analogue and its underlying mechanisms on induced DN in rats Materials and Methods Sixty rats were divided into control group, diabetic group, and liraglutide‐treated group. At the end of experiment, renal CTGF and BMP‐7 messeger RNA expression were determined. Blood sugar, serum urea, and creatinine were measured. Also, histopathological changes were studied. Results Liraglutide can improve renal alterations associated with diabetes as it reduced CTGF expression and increased BMP‐7 expression. In the same time, it could improve histopathological changes and renal function tests. Conclusion These findings influence the beneficial use of liraglutide for the management of DN in patients with diabetes mellitus. GLP‐1 analogue as liraglutide has a therapeutic affect on diabetic nephropathy (DN). GLP‐1 analogue as liraglutide downregulates the expression of CTGF. GLP‐1 analogue as liraglutide upregulates the expression of BMP‐7. Liraglutide improves renal function and histopathological alterations in DN.